Manufacturing Considerations for Clinical Uses of Therapies Derived from Stem Cells

Methods in Enzymology

Volumn 420, Issue , 2006, Pages 410-430

  Weber, Darin J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

BIOLOGICAL SPECIMEN BANKS; GOVERNMENT REGULATION; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; STEM CELL TRANSPLANTATION; STEM CELLS; UNITED STATES;

ANIMALIA;

EID: 33845193115     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(06)20020-X     Document Type: Review

References (32)

1. Combination Products Regulation. Title 21 US Code of Federal Regulations, Part 3.2(e).
2. Donor Eligibility Regulation. Title 21 US Code of Federal Regulations, Part 1271.45.
3. Exemptions and Alternatives Regulation. Title 21 US Code of Federal Regulations, Part 1271.155.
4. Federal Food, Drug and Cosmetic Act, Title 21, USC §321(g), §201(g).
5. General Biological Product Standards Regulation. Title 21 US Code of Federal Regulations, Part 610.
6. Genzyme Biosurgery. Epicel Package Insert (2002). http://www.genzymebiosurgery.com/pdfs/epicel_package_insert.pdf
7. Good Manufacturing Practices Regulation. Title 21 US Code of Federal Regulations, Parts 210 and 211.
8. International Conference on Harmonization. Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (1997)
9. International Conference on Harmonization. Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products (1997)
10. International Organization for Standardization. "Biological Evaluation of Medical Devices-Part 1: Evaluation and Testing,". 2nd ed. (1997), ISO, Geneva ISO 10993-1
11. Investigational New Drug Applications. Title 21, US Code of Federal Regulations, Part 312.
12. Kessler D.A., Siegel J.P., Noguchi P.D., et al. Regulation of somatic cell therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 329 (1993) 1169-1173
13. Title 21 US Code of Federal Regulations. Medical Devices Regulation. Title 21 US code of Federal Regulations, Part 814.
14. Public Health Service Act. Title 42, USC §262, §351.
15. US Food and Drug Administration. Application of current statutory authorities to human somatic cell therapy products and gene therapy products: Notice. Federal Register (1993) 53248 58FR
16. US Food and Drug Administration. Guidance for industry: Guidance for Human Somatic Cell Therapy and Gene Therapy (1998)
17. US Food and Drug Administration. Guidance for Industry Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors (2000)
18. US Food and Drug Administration. Biologics Response Modifiers Advisory Committee. FDA briefing document. 2000 July 13-14. Human Stem Cells as Cellular Replacement Therapies for Neurological Disorders (2000). http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3629b1.htm Available at
19. US Food and Drug Administration. Letter from B. Schwetz, Office of the Commissioner, to Senator Edward Kennedy, 8 September 2001. Available at (2001). http://www.fda.gov/oc/stemcells/kennedyltr.html
20. US Food and Drug Administration. Biologics Response Modifiers Advisory Committee. 2003 Oct. 09-10. Available at. Allogeneic pancreatic islets for the treatment of type 1 diabetes, FDA briefing document (2003). www.fda.gov/ohrms/dockets/ac/03/briefing/3986b1.htm
21. US Food and Drug Administration. Guidance For Industry: Comparability Protocols-Chemistry, Manufacturing, and Controls Documentation (2003)
22. US Food and Drug Administration. Guidance for Industry Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans (2003)
23. US Food and Drug Administration. Draft Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Control (CMC) Reviewers of Human Somatic Cell Therapy Investigational New Drug Applications (INDs) (2003)
24. US Food and Drug Administration. Draft Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) (2004)
25. US Food and Drug Administration. Biologics Response Modifiers Advisory Committee. Cellular products for the treatment of cardiac disease, FDA briefing document (2004). 2004 Mar 18. Available at www.fda.gov/ohrms/dockets/ac/04/briefing/4018b1.htm
26. US Food and Drug Administration. Guidance for Industry Sterile Drug Products Produced by Aseptic Processing-Current Good Manufacturing Practice (2004)
27. US Food and Drug Administration. Draft Guidance for Industry: Gene Therapy Clinical Trials-Observing Participants for Delayed Adverse Events (2005)
28. US Food and Drug Administration. Cellular, Tissue and Gene Therapies Advisory Committee. Potency Measurements for Cellular and Gene Therapy Products. FDA briefing document (2006). 2006 Feb. 09-10. Available at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4205B1-index.htm
29. US Food and Drug Administration. Cellular, Tissue and Gene Therapies Advisory Committee. Cellular Products for Joint Surface Repair. FDA briefing document (2005). 2005 Mar 03. Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4093b2.htm
30. United States Pharmacopoeia. <1043> Ancillary Materials for Cell, Gene, and Tissue-engineered Therapy Products. USP 29-NF 24 (2006)
31. Weber D.J. Biosafety considerations for cell-based therapies. BioPharm. Int. 17 (2004) 48-55
32. Weber D.J. Navigating FDA regulations for human cells and tissues. BioProcessing Int. 2 8 (2004) 22-26